◀ Back to BCL2
BCL2 — CDK2
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Pathan et al., Neoplasia (New York, N.Y.) 2001
:
Comparison of a variety of pharmacological inhibitors of serine/threonine-specific protein kinases demonstrated that the
cyclin dependent kinase inhibitor, flavopiridol, selectively
blocks Bcl-2 phosphorylation induced by antimicrotubule drugs
Pathan et al., Neoplasia (New York, N.Y.) 2001
:
Comparison of a variety of pharmacological inhibitors of serine/threonine-specific protein kinases demonstrated that the
cyclin dependent kinase inhibitor, flavopiridol, selectively
blocks Bcl-2 phosphorylation induced by antimicrotubule drugs
Crescenzi et al., Ann N Y Acad Sci 2002
(Endometrial Neoplasms) :
Association of
Bcl-2 with cyclin a/Cdk-2 complex and its
effects on
Cdk-2 activity
Li et al., Lab Invest 2008
(Cerebellar Neoplasms...) :
Induction of
Cdk2 kinase activity was involved in mediating the cell cycle progression effects, and downregulation of
Bcl-XL was
involved in mediating the proapoptotic effects of HGF downstream of c-Myc
Veliz et al., Cancer Control 2012
(Leukemia, Lymphocytic, Chronic, B-Cell...) :
These investigational agents include rituximab, alemtuzumab, ofatumumab, bendamustine, high-dose methylprednisolone, lenalidomide, lumiliximab,
cyclin dependent kinase inhibitors, small modular immunopharmaceuticals,
Bcl-2 inhibitors , and histone deacetylase inhibitors
Zhan et al., PloS one 2012
:
The forced activation of cyclin
A-Cdk2 in these cells by the overexpression of cyclin A, triggered Rad9 phosphorylation at serine 328 and thereby
promoted the interaction of Rad9 with
Bcl-xL and the subsequent initiation of the apoptotic program
Gil-Gómez et al., EMBO J 1998
:
We found that
Cdk2 activation during thymocyte apoptosis can be
regulated by p53, Bax and
Bcl-2